Insmed Incorporated granted inducement awards to 128 new employees under its 2025 Inducement Plan, following approval by the company’s Compensation Committee. The awards, made to support the employees’ entry into employment and comply with Nasdaq Listing Rule 5635(c)(4), comprise 115,320 restricted stock units (company shares that vest over time) and options covering 5,560 shares. The grants were made on Aug. 31, 2026, with the options priced at $121.82 per share, the closing trading price on the Nasdaq Global Select Market that day. Both award types follow four-year vesting schedules, while the options have a 10-year term. Insmed is a Bridgewater, New Jersey-based biopharmaceutical company developing approved and investigational medicines in respiratory, immunology and inflammation, and neuro and other rare diseases.